HealthMore in Health →
FDA Reopens a Rare Cancer Drug Review After a Surprise Rejection
The FDA is reconsidering Ebvallo after a prior rejection, following an agreement with the companies developing the treatment to address the agency’s main concern.
Key Takeaways
- The FDA is reconsidering Ebvallo after previously rejecting the treatment.
- STAT’s candidate metadata describes the earlier decision as a surprise rejection.
DE
DT Editorial AI··via statnews.com